BeOne Medicines (ONC) Cash & Equivalents (2015 - 2026)
BeOne Medicines' (ONC) quarterly Cash & Equivalents came in at $4.8 billion in Q1 2026, up 90.42% year-on-year from $2.5 billion in Q1 2025, and up 5.37% on a QoQ basis from $4.5 billion in Q4 2025.
BeOne Medicines (ONC) Cash & Equivalents (2015 - 2026) Analysis & Trends
BeOne Medicines (ONC) has 12 years of Cash & Equivalents data on file, last reported at $4.8 billion in Q1 2026.
- On a quarterly basis, Cash & Equivalents rose 90.42% year-over-year to $4.8 billion in Q1 2026; TTM through Mar 2026 was $4.8 billion, a 90.42% increase from a year earlier, with the FY2025 full-year figure at $4.5 billion, up 73.08% from the prior year.
- Cash & Equivalents for Q1 2026 stood at $4.8 billion, up from $4.5 billion in the prior quarter.
- Over the last five years, Cash & Equivalents for ONC reached as high as $4.8 billion in Q1 2026 and fell as low as $191000.0 in Q3 2022.
- Historically, Cash & Equivalents has averaged $3.0 billion across 5 years, with a median of $3.1 billion in 2023.
- Across the five-year window, Cash & Equivalents slumped 99.99% in 2022 and jumped 1605835.08% in 2023, its largest moves.
- Year by year, Cash & Equivalents stood at $3.9 billion in 2022, then retreated by 18.03% to $3.2 billion in 2023, then decreased by 17.16% to $2.6 billion in 2024, then jumped by 73.08% to $4.5 billion in 2025, then increased by 5.37% to $4.8 billion in 2026.
- Per Business Quant data, the three most recent Cash & Equivalents figures were $4.8 billion in Q1 2026, $4.5 billion in Q4 2025, and $4.0 billion in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 82.45 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 61.40 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 4.79 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 32.26 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 5.49 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 2.96 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 3.58 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 440.94 Mn |
| 10 | Alnylam Pharmaceuticals | 35.71 Bn | 32.70 Bn | 959.66 Mn | 1.71 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.79 Bn |
| Dec 31, 2025 | 4.55 Bn |
| Sep 30, 2025 | 4.04 Bn |
| Jun 30, 2025 | 2.76 Bn |
| Mar 31, 2025 | 2.52 Bn |
| Dec 31, 2024 | 2.63 Bn |
| Sep 30, 2024 | 2.70 Bn |
| Jun 30, 2024 | 2.59 Bn |
| Mar 31, 2024 | 2.79 Bn |
| Dec 31, 2023 | 3.17 Bn |
| Sep 30, 2023 | 3.07 Bn |
| Jun 30, 2023 | 3.41 Bn |
| Mar 31, 2023 | 3.54 Bn |
| Dec 31, 2022 | 3.87 Bn |
| Sep 30, 2022 | 191,000.00 |
| Jun 30, 2022 | 4.53 Bn |
| Mar 31, 2022 | 330,000.00 |
| Dec 31, 2021 | 328,000.00 |
| Sep 30, 2021 | 1.38 Bn |
| Jun 30, 2021 | 310,000.00 |